Pfizer is contending with three significant headwinds in 2026. First, the company trails behind competitors in the rapidly expanding GLP-1 weight-loss drug market, where rivals have captured a larger share of prescriptions and commanding price points. Second, Pfizer is approaching patent expiration dates for several of its top-selling products: Ibrance in 2027, and both Eliquis and Vyndaqel in 2028. The imminent loss of exclusivity could expose Pfizer’s revenue stream to generic competition, threatening annual sales that collectively exceed $20 billion. Third, the company’s dividend payout ratio has climbed to nearly 100% of free cash flow, raising concerns that Pfizer may need to reduce or suspend its dividend if cash generation falters under market pressure or increased R&D investment demands.

Analysts forecast Pfizer’s fourth-quarter earnings per share at $0.57, down from $0.63 in the same period last year, while consensus revenue estimates stand at $16.83 billion versus $17.76 billion a year earlier. This expected decline reflects reduced sales of pandemic-related products and increased spending on R&D and marketing for newer therapies. On January 20, Pfizer signed a licensing agreement to use Novavax’s Matrix-M adjuvant, a deal anticipated to bolster its vaccine portfolio but unlikely to significantly offset near-term revenue headwinds. Ahead of the earnings call on February 3, several of the most accurate analysts have adjusted their full-year 2026 EPS forecasts downward, citing slower uptake of growth drivers and margin pressure.

Despite current challenges, Pfizer remains one of the world’s largest and most diversified pharmaceutical companies, with a robust pipeline that includes oncology, immunology and rare disease candidates. Management has signaled plans to trim operating expenses by up to $1.5 billion over the next two years and to prioritize high-value assets in clinical development. However, the near-total payout of free cash flow to dividends underscores the need for cautious income-focused investors. Should generic competition erode blockbuster revenues as expected, Pfizer may face diminishing flexibility to sustain its current dividend level without straining its balance sheet.